Breaking News
Long-acting injectable medicine as potential route to COVID-19 therapy
CELT was established as part of a £30.5 million ($40m) international research consortium, primarily funded by Unitaid
Linkam FDCS196 stage used in risperidone research
The researchers aimed to develop a novel transdermal delivery system for the anti-psychotic drug
Alternating vaccines trial expands to include two additional vaccines
Volunteers, who will have received either the Oxford-AstraZeneca, or Pfizer vaccine, will be randomly allocated to ...
Bispecific antibodies in review: from cell line development to manufacturing
With the advent of a technology that targets two different epitopes simultaneously, growth in the global bispecific ...
Long-term toxicology studies confirm MP1032 safety profile
MetrioPharm's lead compound has been evaluated in dogs and rats, confirming its "very good tolerability"
Merck and SignalChem to investigate combination tumour treatment
The companies will evaluate SignalChem’s SLC-391 in combination with Merck’s Keytruda (pembrolizumab) in the ...
From dark art to an age of enlightenment
Much is happening in the realms of Almac’s GMP peptides business in terms of growth, development and strategic ...
IONTAS identifies SARS-CoV-2 variant neutralising antibodies
The company is now seeking development partners to progress the antibodies
Celonic Group and UCL announce partnership
The agreement gives UCL access to Celonic’s CHOvolution platform
Bispecific antibodies: an exciting new class of emerging therapeutics
Since 2015, when the first bispecific received US FDA approval, these game-changing antibodies have rocketed in ...
The application of picodroplet technology for biopharmaceutical discovery and scientific research
Picodroplet technologies continue to push the boundaries of biologic discovery by accelerating research, expanding the ...
Why the production of bispecific antibodies depends on early stage product characterisation
Chloe Ackaert, Senior Scientist, and Sofie Pattijn, Chief Technology Officer and founder, ImmunXperts a Nexelis group ...
Almac Group announces PhD scholarship at UCL
This investment follows the company’s announcement it completed an R&D centre within which its programme to ...
UK Government invests in CPI to develop vaccine library
When variants of COVID-19 are identified, their DNA can be used to develop mRNA vaccines in a matter of days, CPI says
In Brief
Most Popular
- NerPharMa and ICROM partner on highly potent drugs and ADC-payloads
- Beximco Pharma introduces first generic remdesivir for COVID-19
- BioVaxys and BioElpida agree to begin ovarian cancer vaccine bioproduction
- Tabletability, compactability and compressibility: What’s the difference?
- Advances in technology and support for Direct-to-Patient (DTP) services
Inspiration and Learning
People
- Thomas Fricke appointed Commercial Director of IMA Pharma
- Metrion Biosciences appoints Non-Executive Director
- Stablepharma appoints ex IQVIA & Pfizer executive as CEO
- CellGenix appoints Daniel Spatz VP Sales, Marketing & Logistics
- SmartAnalyst appoints Sasha Richardson CEO
- Vifor Pharma to propose Åsa Riisberg for board of directors
- Follicum appoints CEO and establishes Chief Scientific Officer role
- Nordic Nanovector appoints Peter Braun CEO
